Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of B-3E07 vs Forsteo in Healthy Adult Females
NCT07497503Phase 1Recruiting
- Sponsor
- Syneos Health
- Start
- Apr 2026
- Primary completion
- Sep 2026
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of B-3E07 in osteoporosis (2 arms), sponsored by Syneos Health. Primary endpoints: Maximum Plasma Concentration and Area Under the Plasma Concentration-time Curve From Time Zero to Infinity. Started Apr 2026; status: recruiting.
02
Drugs
B-3E07
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT07497503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07497503.